Theravance Biopharma, Inc. Payments to Acquire Available-for-sale Securities
Theravance Biopharma, Inc. (TBPH) reported Payments to Acquire Available-for-sale Securities of $288.79 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-02-28
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $2.97M, a 95.70% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $53.83M, a 30.25% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $72.77M, a 20.36% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-03-31 was $159.22M.
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for fiscal 2017 was $288.79M, a 21.56% increase from fiscal 2016.
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for fiscal 2016 was $237.57M, a 225.39% increase from fiscal 2015.
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for fiscal 2015 was $73.01M, a 56.77% decline from fiscal 2014.
- Theravance Biopharma, Inc. payments to acquire available-for-sale securities for fiscal 2014 was $168.89M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $56.80M derived: sum of 2 quarters · filed 2018-02-28 | $129.57M derived: sum of 3 quarters · filed 2018-02-28 | $288.79M 10-K · filed 2018-02-28 |
| 2017-09-30 | $53.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $126.60M derived: sum of 2 quarters · filed 2017-11-08 | $285.82M 10-Q · filed 2017-11-08 | $354.83M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-06-30 | $72.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $231.99M 10-Q · filed 2017-08-09 | $301.00M derived: sum of 3 quarters · filed 2018-02-28 | $378.18M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-03-31 | $159.22M 10-Q · filed 2017-05-10 | $228.22M derived: sum of 2 quarters · filed 2018-02-28 | $305.40M derived: sum of 3 quarters · filed 2018-02-28 | $396.78M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-12-31 | $69.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $146.19M derived: sum of 2 quarters · filed 2018-02-28 | $237.57M derived: sum of 3 quarters · filed 2018-02-28 | $237.57M 10-K · filed 2018-02-28 |
| 2016-09-30 | $77.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $168.56M derived: sum of 2 quarters · filed 2017-11-08 | $168.56M 10-Q · filed 2017-11-08 | $230.51M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $91.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $91.38M 10-Q · filed 2017-08-09 | $153.33M derived: sum of 3 quarters · filed 2018-02-28 | $153.33M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | $61.95M derived: sum of 2 quarters · filed 2018-02-28 | $61.95M derived: sum of 3 quarters · filed 2018-02-28 | $62.35M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $61.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $61.95M derived: sum of 2 quarters · filed 2018-02-28 | $62.35M derived: sum of 3 quarters · filed 2018-02-28 | $73.01M 10-K · filed 2018-02-28 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $400.00K derived: sum of 2 quarters · filed 2016-11-09 | $11.06M 10-Q · filed 2016-11-09 | $34.08M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $11.06M 10-Q · filed 2016-08-09 | $34.08M derived: sum of 3 quarters · filed 2017-03-01 | $169.97M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $10.66M 10-Q · filed 2016-05-10 | $33.68M derived: sum of 2 quarters · filed 2017-03-01 | $169.57M derived: sum of 3 quarters · filed 2017-03-01 | $179.55M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $23.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $158.91M derived: sum of 2 quarters · filed 2017-03-01 | $168.89M derived: sum of 3 quarters · filed 2017-03-01 | $168.89M 10-K · filed 2017-03-01 |
| 2014-09-30 | $135.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $145.87M derived: sum of 2 quarters · filed 2015-11-12 | $145.87M 10-Q · filed 2015-11-12 | $145.87M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $9.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $9.98M 10-Q · filed 2015-08-13 | $9.98M derived: sum of 3 quarters · filed 2016-03-11 | $9.98M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-13 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 10-K · filed 2016-03-11 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $0.00 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-14 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |